<DOC>
	<DOC>NCT01120717</DOC>
	<brief_summary>The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>A Study to Assess the Long-term Safety of QVA149</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male or female adults aged ≥40 yrs Smoking history of at least 10 pack years Diagnosis of COPD (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) Postbronchodilator FEV1 &lt; 80% and ≥ 30% of the predicted normal value and postbronchodilator FEV1/FVC (forced vital capacity) &lt;70% Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1 Patients with concomitant pulmonary disease Patients with a history of asthma Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Patients with a known history and diagnosis of alpha1 antitrypsin deficiency Patients in the active phase of a supervised pulmonary rehabilitation program Patients contraindicated for inhaled anticholinergic agents and β2 agonists Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>QVA149</keyword>
	<keyword>COPD</keyword>
	<keyword>combination bronchodilator</keyword>
</DOC>